Josh's Shared Resources

Advancing Treatment for Treatment-Resistant Schizophrenia: Challenges and New Approaches
Treatment-resistant schizophrenia (TRS) impacts nearly one-third of patients who do not respond to dopamine-blocking antipsychotic medications....

Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University

Treatment-Resistant Schizophrenia: Challenges and Pathways Forward
Treatment-resistant schizophrenia (TRS) is defined by persistent positive symptoms despite trials with at least two different antipsychotics at adequate dose...

Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University

Study Finds No Clear Advantage of CBT Over Other Therapies for Schizophrenia
Authors of this Cochrane Review assessed the effectiveness of cognitive behavioral therapy (CBT) compared to other psychosocial therapies when used...

Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University

Researchers Investigate Relapse Risk and Predictors in Those With Schizophrenia Withdrawn From Treatment
This study quantified the risk and predictors of relapse among individuals with schizophrenia withdrawn from antipsychotic maintenance treatment....

Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University

Long-Acting Injectable Antipsychotics for Schizophrenia and Bipolar I Disorder
Long-acting injectable antipsychotics (LAIs) are crucial for maintaining treatment in individuals with schizophrenia (SCZ) or bipolar I disorder (BP-I), the...

Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University

Resilience Factors in Schizophrenia: Key Psychological Constructs That May Protect Against Suicide
Suicide is a significant concern for individuals with schizophrenia, but not all individuals with this diagnosis attempt or die by...

Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University